IDH1 and cancer: Specifically, in cells with somatic gain-of-function mutation of IDH, 2-HG accumulation resulted in inhibition of a histone-lysin demethylase KDM4B and associated disturbance of HR repair [16], thus sensitizing cancer cells to PARP inhibition with clinical relevance [7].